| CAGR (2025 - 2035) | 4.2% |
The Thyroid Disorder Market is currently experiencing notable transformations driven by various factors. An increasing prevalence of thyroid disorders, coupled with heightened awareness regarding the importance of early diagnosis and treatment, appears to be propelling market growth. Healthcare providers are increasingly focusing on innovative diagnostic tools and therapeutic options, which may enhance patient outcomes. Furthermore, the integration of advanced technologies in treatment protocols suggests a shift towards more personalized medicine, potentially improving the management of thyroid-related conditions. In addition, the rising demand for effective treatment options is likely to stimulate research and development activities within the pharmaceutical sector. This trend indicates a growing interest in novel therapies, including biologics and targeted treatments, which could redefine standard care practices. As the Thyroid Disorder Market evolves, stakeholders must remain vigilant to emerging trends and adapt strategies accordingly to meet the changing needs of patients and healthcare systems.
There is a growing recognition of thyroid disorders among the general population and healthcare professionals. This heightened awareness is leading to more frequent screenings and early diagnosis, which may contribute to improved patient outcomes.
The Thyroid Disorder Market is witnessing a surge in the adoption of advanced technologies for treatment. Innovations such as minimally invasive surgical techniques and targeted therapies are becoming more prevalent, potentially enhancing the effectiveness of interventions.
A shift towards personalized medicine is becoming evident in the management of thyroid disorders. Tailoring treatment plans to individual patient profiles may improve therapeutic efficacy and patient satisfaction, indicating a significant trend in the market.
North America is the largest market for thyroid disorders, accounting for approximately 45% of the global market share. The region's growth is driven by increasing prevalence of thyroid diseases, heightened awareness, and advancements in treatment options. Regulatory support from agencies like the FDA facilitates faster drug approvals, enhancing market dynamics. The demand for innovative therapies and personalized medicine is also on the rise, further propelling market growth. The United States is the leading country in this region, with significant contributions from Canada. Major pharmaceutical companies such as AbbVie, Eli Lilly, and Merck & Co. are actively involved in developing and marketing thyroid disorder treatments. The competitive landscape is characterized by a focus on research and development, with companies investing heavily in new therapies to meet the growing demand for effective treatment options.
Europe is witnessing significant growth in the thyroid disorder market, holding approximately 30% of the global share. The increasing incidence of thyroid-related conditions, coupled with rising healthcare expenditure, is driving demand for effective treatments. Regulatory frameworks in countries like Germany and France are supportive of innovative therapies, which enhances market accessibility and patient care. The region is also focusing on preventive healthcare measures, which is expected to further boost market growth. Leading countries in Europe include Germany, France, and the UK, where key players like Novartis and Sanofi are making substantial investments. The competitive landscape is marked by collaborations and partnerships aimed at enhancing product offerings. The presence of well-established healthcare systems facilitates the introduction of new therapies, ensuring that patients have access to the latest treatment options available.
The Asia-Pacific region is emerging as a significant player in the thyroid disorder market, accounting for about 20% of the global market share. The growth is driven by increasing awareness of thyroid health, rising disposable incomes, and improvements in healthcare infrastructure. Countries like China and India are witnessing a surge in demand for thyroid treatments, supported by government initiatives aimed at enhancing healthcare access and affordability. Regulatory bodies are also streamlining approval processes for new therapies, fostering market growth. China is the largest market in this region, followed by India, where local and international players are competing to capture market share. Companies like Takeda and Amgen are actively involved in the development of innovative therapies. The competitive landscape is characterized by a mix of multinational corporations and local firms, all striving to meet the growing demand for effective thyroid disorder treatments. This dynamic environment is expected to drive further advancements in the sector.
The Middle East and Africa region is gradually emerging in the thyroid disorder market, holding approximately 5% of the global share. The growth is primarily driven by increasing awareness of thyroid health issues and the rising prevalence of thyroid disorders. Government initiatives aimed at improving healthcare access and affordability are also contributing to market expansion. Regulatory bodies are working to enhance the approval processes for new treatments, which is expected to stimulate market growth in the coming years. Leading countries in this region include South Africa and the UAE, where there is a growing presence of international pharmaceutical companies. The competitive landscape is evolving, with both local and The Thyroid Disorder. Companies are focusing on partnerships and collaborations to enhance their product offerings and meet the increasing demand for effective thyroid disorder treatments.
The Thyroid Disorder Market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing awareness of thyroid-related health issues. Key players such as AbbVie (US), Eli Lilly and Company (US), and Novartis (CH) are strategically positioned to leverage innovation and expand their market presence. AbbVie (US) focuses on developing novel therapies, while Eli Lilly and Company (US) emphasizes partnerships to enhance its product portfolio. Novartis (CH) is actively pursuing regional expansion, particularly in emerging markets, which collectively shapes a competitive environment that is increasingly focused on patient-centric solutions and advanced therapeutic options.
In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The Thyroid Disorder Market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of treatment options, yet the collective strategies of these companies indicate a trend towards consolidation and collaboration, particularly in research and development initiatives.
In August 2025, AbbVie (US) announced a strategic partnership with a leading biotechnology firm to co-develop a new class of thyroid hormone replacement therapies. This collaboration is expected to accelerate the development timeline and enhance the therapeutic efficacy of treatments, thereby positioning AbbVie (US) as a frontrunner in the market. The strategic importance of this partnership lies in its potential to address unmet medical needs and improve patient outcomes, which is increasingly becoming a focal point in the industry.
In September 2025, Eli Lilly and Company (US) launched a digital health platform aimed at improving patient engagement and adherence to thyroid disorder treatments. This initiative reflects a broader trend towards digitalization in healthcare, where technology is utilized to enhance patient experiences and outcomes. The strategic significance of this move is profound, as it not only strengthens Eli Lilly's (US) market position but also aligns with the growing demand for integrated healthcare solutions that prioritize patient-centric care.
In July 2025, Novartis (CH) expanded its manufacturing capabilities in Asia to meet the rising demand for thyroid medications in the region. This expansion is indicative of Novartis's (CH) commitment to regional growth and its strategy to ensure supply chain reliability. The implications of this move are substantial, as it positions Novartis (CH) to better serve a burgeoning market while also mitigating potential supply chain disruptions that could arise from global uncertainties.
As of October 2025, current competitive trends in the Thyroid Disorder Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are shaping the landscape, fostering innovation and enhancing the development of advanced therapies. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and the reliability of supply chains, thereby ensuring that companies remain agile and responsive to the ever-changing healthcare environment.
Recent development in the thyroid disorder market are
• In November 2015, a program that focuses on managing the daily routine of those having the life-long condition of hypothyroidism was launched by Abbie under Good Morning Hypothyroidism (GMH).
• In October 2016, ThyroTest was introduced by Abbott acquired Alere Inc., a service provider organization and a diagnostic device manufacturer introduced in the market, which is a test to detect hypothyroidism.
• In March 2018, an orally available tyrosine kinase inhibitor was discovered by Eisai.
• Also, in the same month, it was announced by Eisai Co Ltd and Merck about their strategic collar radiation. They are popularly called MSD after the collaboration.
• The commercialization of LENVIMA was also done in the year 2018.
Le marché des troubles thyroïdiens devrait faire croître at et 4.2% TCAC de 2024 à 2035, grâce à la prévalence croissante, aux progrès des diagnostics in et aux options de traitement améliorées.
De nouvelles opportunités résident dans :
D’ici 2035, le marché des troubles thyroïdiens devrait connaître une croissance et une innovation substantielles.
| MARKET SIZE 2024 | 2.511(USD Billion) |
| MARKET SIZE 2025 | 2.617(USD Billion) |
| MARKET SIZE 2035 | 3.948(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.2% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Market analysis in progress |
| Segments Covered | Market segmentation analysis in progress |
| Key Market Opportunities | Integration of telemedicine and digital health solutions in the Thyroid Disorder Market. |
| Key Market Dynamics | Rising prevalence of thyroid disorders drives demand for innovative treatment options and enhanced diagnostic technologies. |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Le marché des troubles thyroïdiens devrait atteindre une valorisation de 3.948 USD Billion d’ici 2035.
In 2024, le marché des troubles thyroïdiens a été évalué at 2.511 USD Billion.
Le TCAC attendu pour le marché des troubles thyroïdiens au cours de la période de prévision 2025 - 2035 est 4.2%.
Les principaux acteurs sur le marché des troubles thyroïdiens comprennent AbbVie, Bristol-Myers Squibb, Eli Lilly and Company et Merck & Co.
D'ici 2035, les revenus projetés pour l'hypothyroïdie sont de 2.368 USD Billion, tandis que pour l'hyperthyroïdie, ils devraient atteindre 1.58 USD Billion.
Les revenus projetés pour les options de traitement par 2035 incluent les médicaments at 1.949 USD Billion, la chirurgie at 1.174 USD Billion et la thérapie à l'iode radioactif at 0.825 USD Billion.
D’ici 2035, la voie d’administration orale devrait générer 1.951 USD Billion, indiquant son rôle important in sur le marché des troubles thyroïdiens.
D'ici 2035, les hôpitaux devraient générer 1.563 USD Billion, les cliniques 1.174 USD Billion et autres 1.211 USD Billion.
La croissance du marché des troubles thyroïdiens, avec un TCAC projeté de 4.2%, suggère une expansion constante par rapport aux autres secteurs de la santé.
Des facteurs tels que les progrès des options de traitement in et la sensibilisation croissante aux troubles thyroïdiens peuvent influencer la croissance du marché des troubles thyroïdiens.
Satyendra Maurya
Rahul Gotadki
The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed endocrinology journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Drug Evaluation and Research, European Medicines Agency (EMA) Human Medicines Division, Pharmaceuticals and Medical Devices Agency (PMDA) Japan, American Thyroid Association (ATA) Guidelines Repository, European Thyroid Association (ETA) Clinical Practice Guidelines, The Endocrine Society, American Association of Clinical Endocrinologists (AACE), National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Centers for Disease Control and Prevention (CDC) National Center for Health Statistics National Health and Nutrition Examination Survey (NHANES), World Health Organization (WHO) Global Health Observatory, IQVIA National Prescription Audit (NPA), Symphony Health Integrated Dataverse (IDV), Cochrane Library Endocrinology Collection, PubMed/MEDLINE Thyroid Research Database, Centers for Medicare & Medicaid Services (CMS) Physician/Supplier Procedure Summary, Eurostat Healthcare Statistics, OECD Health Statistics, and national endocrinology society reports from key markets including the British Thyroid Foundation, Thyroid Federation International, and Japan Thyroid Association. These sources were used to collect prescription volume data, drug approval databases (levothyroxine, liothyronine, methimazole, propylthiouracil), radioactive iodine therapy procedure statistics, thyroidectomy surgical volumes, epidemiological prevalence data for autoimmune thyroiditis and Graves' disease, reimbursement codes, and clinical safety studies for hormone replacement therapies and antithyroid agents.
In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. Chief Medical Officers, Heads of Endocrine Therapeutics, Global Brand Presidents for Thyroid Portfolios, regulatory affairs directors, and commercial strategy leads from pharmaceutical companies creating biologic agents, TSH suppressive treatments, and synthetic thyroid hormones were examples of supply-side sources. Board-certified endocrinologists, thyroid surgeons, nuclear medicine doctors, hospital pharmacy directors, clinical pharmacists, and procurement leads from academic medical centers, endocrinology specialty clinics, integrated health networks, and ambulatory surgical centers were among the demand-side sources. In addition to gathering information on generic substitution rates, brand loyalty in hormone replacement therapy, radioactive iodine dosing protocols, and reimbursement dynamics for thyroid function testing versus pharmaceutical interventions, primary research validated treatment protocol adoption patterns and confirmed pipeline drug development timelines (including TSH receptor monoclonal antibodies and next-generation thyromimetics).
Primary Respondent Breakdown:
• By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)
• By Region: North America (38%), Europe (25%), Asia-Pacific (28%), Rest of World (9%)
Global market valuation was derived through revenue mapping, prescription volume analysis, and procedure data triangulation. The methodology included:
• Identification of 35+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America specializing in thyroid hormone replacement therapies (levothyroxine sodium, liothyronine), antithyroid medications (thioamides), and diagnostic agents (radioactive iodine isotopes)
• Product mapping across hypothyroidism treatments, hyperthyroidism therapeutics, thyroid hormone suppressive therapies, and adjuvant care segments
• Analysis of reported and modeled annual revenues specific to thyroid disorder drug portfolios, including branded and generic market share splits
• Coverage of manufacturers representing 75-80% of global market share in 2024
• Extrapolation using bottom-up (prescription volume × ASP by country/region, thyroidectomy procedure volumes × surgical costs, radioactive iodine therapy sessions × reimbursement rates) and top-down (manufacturer revenue validation, IQVIA audit data reconciliation) approaches to derive segment-specific valuations for oral levothyroxine, intravenous thyroid formulations, and surgical intervention markets
Veuillez remplir le formulaire ci-dessous pour recevoir un échantillon gratuit de ce rapport
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah Malgeri
Co-Founder
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkamp
Account and Business Manager
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan Choi
Senior Retail Manager
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Mark Irwin
Management Consultant
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif Moroglu
Strategy & Business Development Director
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
Guilherme Gomes Martins
Product Management Director
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph Aguayo
Sales Operations & Pricing Manager
“Thank you, this will be very helpful for OQS.”
La Terria Dodd
Program Support Specialist
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA
